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LETTER TO THE EDITOR
Inappropriate Use of Radioactive Iodine
for Low-Risk Papillary Thyroid Cancer Is Most Common
in Regions with Poor Access to Healthcare
Jennifer L. Marti,1 Louise Davies,2 Megan R. Haymart,3 Benjamin R. Roman,4
R. Michael Tuttle,5 and Luc G.T. Morris4
Dear Editor:
American Thyroid Association guidelines recommend
against routine use of postoperative radioactive iodine (RAI)
for low-risk thyroid cancers such as papillary thyroid carci-
nomas (PTC) £1 cm (1). Inappropriate use of RAI places
patients at unnecessary risk of permanent treatment-related
toxicity and secondary cancers.
We have previously shown that county-level access to
healthcare affects the likelihood that a small thyroid cancer
will be diagnosed (2). We hypothesized that these same
factors would be associated with the likelihood of receiving
inappropriate RAI treatment for low-risk PTC.
Using the National Cancer Institute’s Surveillance, Epi-
demiology, and End Results (SEER) database, we performed
an ecologic analysis across 337 U.S. counties, encompassing
13,401 patients undergoing thyroidectomy from 1983 to 2009
for low-risk (£1 cm intrathyroidal N0 M0) PTC. We modeled
county-level access to healthcare with eight socioeconomic
factors known to be indicative of access to care, in population-
weighted least squares regression: mean family income and
percentage of residents uninsured, unemployed, in poverty,
white-collar employed, non-English speaking, only high-school
educated, and college educated (2,3).
All socioeconomic indices of lower healthcare access
correlated with a higher likelihood of RAI treatment, with
healthcare access explaining a significant proportion of
county-level variation (r = 0.41, r2 = 0.17, p < 0.001; Fig. 1).
There was wide variation in RAI treatment for low-risk PTC
across counties (range 0–100%). In 42 counties with ‡50
cases, the range was 9.6–56.1%. In counties in the highest
decile of access to care, RAI was used in 30% of patients; in
counties in the lowest decile, 42% ( p = 0.04). Between 1983
and 2009, the proportion of U.S. patients receiving RAI for
low-risk PTCs increased from 8% to 31% ( p < 0.001).
These data demonstrate a significant association between
poorer access to healthcare and inappropriate use of adjuvant
RAI for low-risk PTC. We caution that ecologic analyses
such as this cannot prove causation but are a useful tool for
showing problems with quality of care. Variation in clinical
practice, such as observed here, generally suggests that
quality of care may be suboptimal, as it implies that some
patients are undertreated, or overtreated, or both. Such vari-
ation may represent clinical uncertainty in the field, but can
also represent physician or patient preferences.
Haymart et al. reported that the likelihood of a young
patient receiving RAI for a stage I PTC ranged from 0% to
90% across 397 U.S. hospitals. The majority of the variation
in RAI use could not be explained by patient, tumor, or
hospital factors, and was attributable only to ‘‘unexplained
hospital characteristics’’ (4). In subsequent work, Haymart
et al. have shown that RAI use is associated with the specialty
of the primary decision maker (nuclear medicine physicians
FIG. 1. Correlation of county-level socioeconomic markers
of access to healthcare with the use of RAI for very low-risk
papillary thyroid carcinoma. HS, high school; RAI, radio-
active iodine.
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were more likely than endocrinologists, and surgeons less
likely, to administer RAI), and with practice setting (nonac-
ademic physicians were more likely than academic physi-
cians to administer RAI) (5,6).
Here, we found that inappropriate treatment with RAI
was most common in areas of the United States with less
access to healthcare. There are a number of potential ex-
planations for these findings. These may reflect differences
in the intensity of care physicians are accustomed to de-
livering in populations with less access to care and poorer
overall health. However, we did restrict analysis to cancers
in which RAI is not recommended. Alternatively, these
findings may reflect differences in access to experienced
specialists, market forces, or other unmeasured factors.
These data provide an opportunity to reinforce guidelines
recommending against aggressive therapy of low risk PTCs,
which remains common.
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